Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Peri

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Angewandte Chemie (International Ed. in English)|March 28, 2007
Inhibition of lipid a stimulated activation of human dendritic cells and macrophages by amino and hydroxylamino monosaccharidesFrancesco Peri, Francesca Granucci, Barbara Costa, et al.
Atherosclerosis|August 31, 2015
A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms developmentChristopher Huggins, Stuart Pearce, Francesco Peri, et al.
Biochemical Pharmacology|July 6, 2010
The cationic amphiphile 3,4-bis(tetradecyloxy)benzylamine inhibits LPS signaling by competing with endotoxin for CD14 bindingMatteo Piazza, Valentina Calabrese, Chiara Baruffa, et al.
Innate Immunity|September 14, 2018
The synthetic glycolipid-based TLR4 antagonist FP7 negatively regulates in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signallingCharys Palmer, Francesco Peri, Frank Neumann, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|May 3, 2003
Conformational features of a synthetic model of the first extracellular loop of the angiotensin II AT1A receptorGiuseppe Nicastro, Francesco Peri, Lorella Franzoni, et al.
Bioorganic & Medicinal Chemistry|March 12, 2002
Novel Tn antigen-containing neoglycopeptides: synthesis and evaluation as anti tumor vaccinesLaura Cipolla, Maria Rescigno, Antonella Leone, et al.
International Journal of Molecular Sciences|November 11, 2022
A Global Picture of Molecular Changes Associated to LPS Treatment in THP-1 Derived Human Macrophages by Fourier Transform Infrared MicrospectroscopyDiletta Ami, Ana Rita Franco, Valentina Artusa, et al.
Glia|July 11, 2008
Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in miceIsabella Bettoni, Francesca Comelli, Clara Rossini, et al.
Innate Immunity|April 16, 2021
Synthetic glycolipid-based TLR4 antagonists negatively regulate TRIF-dependent TLR4 signalling in human macrophagesCharys Palmer, Fabio A Facchini, Richard Po Jones, et al.
Chemmedchem|December 6, 2011
A synthetic lipid A mimetic modulates human TLR4 activityMatteo Piazza, Valentina Calabrese, Gaetana Damore, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Angewandte Chemie (International Ed. in English)|March 28, 2007
Inhibition of lipid a stimulated activation of human dendritic cells and macrophages by amino and hydroxylamino monosaccharidesFrancesco Peri, Francesca Granucci, Barbara Costa, et al.
Atherosclerosis|August 31, 2015
A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms developmentChristopher Huggins, Stuart Pearce, Francesco Peri, et al.
Biochemical Pharmacology|July 6, 2010
The cationic amphiphile 3,4-bis(tetradecyloxy)benzylamine inhibits LPS signaling by competing with endotoxin for CD14 bindingMatteo Piazza, Valentina Calabrese, Chiara Baruffa, et al.
Innate Immunity|September 14, 2018
The synthetic glycolipid-based TLR4 antagonist FP7 negatively regulates in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signallingCharys Palmer, Francesco Peri, Frank Neumann, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|May 3, 2003
Conformational features of a synthetic model of the first extracellular loop of the angiotensin II AT1A receptorGiuseppe Nicastro, Francesco Peri, Lorella Franzoni, et al.
Bioorganic & Medicinal Chemistry|March 12, 2002
Novel Tn antigen-containing neoglycopeptides: synthesis and evaluation as anti tumor vaccinesLaura Cipolla, Maria Rescigno, Antonella Leone, et al.
International Journal of Molecular Sciences|November 11, 2022
A Global Picture of Molecular Changes Associated to LPS Treatment in THP-1 Derived Human Macrophages by Fourier Transform Infrared MicrospectroscopyDiletta Ami, Ana Rita Franco, Valentina Artusa, et al.
Glia|July 11, 2008
Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in miceIsabella Bettoni, Francesca Comelli, Clara Rossini, et al.
Innate Immunity|April 16, 2021
Synthetic glycolipid-based TLR4 antagonists negatively regulate TRIF-dependent TLR4 signalling in human macrophagesCharys Palmer, Fabio A Facchini, Richard Po Jones, et al.
Chemmedchem|December 6, 2011
A synthetic lipid A mimetic modulates human TLR4 activityMatteo Piazza, Valentina Calabrese, Gaetana Damore, et al.
Pageof 10